|
US513030A
(en)
|
|
1894-01-16 |
|
Machine for waxing or coating paper |
|
US2878264A
(en)
|
|
1959-03-17 |
|
Substituted amino alcohols |
|
DE1144279B
(de)
|
1957-09-26 |
1963-02-28 |
Robins Co Inc A H |
Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
|
|
US3135766A
(en)
|
1961-10-03 |
1964-06-02 |
Mead Johnson & Co |
3-substituted-3-pyrrolidinols
|
|
US3484473A
(en)
|
1967-05-12 |
1969-12-16 |
Buckman Labor Inc |
Methylene bisesters of thiolsulfonic acids
|
|
DE1934150A1
(de)
|
1968-07-10 |
1970-01-15 |
Pennwalt Corp |
Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
|
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US3745162A
(en)
|
1970-08-31 |
1973-07-10 |
Robins Co Inc A H |
1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
|
|
GB1448437A
(en)
|
1973-02-24 |
1976-09-08 |
Beecham Group Ltd |
Diphenylpropylamines
|
|
US4022791A
(en)
|
1975-06-03 |
1977-05-10 |
Pfizer Inc. |
2-Aminomethyl-3,4-dihydronaphthalenes
|
|
GB1504424A
(en)
|
1975-08-09 |
1978-03-22 |
Beecham Group Ltd |
Isoquinoline-derived aminoethers
|
|
BR7807288A
(pt)
|
1977-11-08 |
1979-06-12 |
Genentech Inc |
Processo para sintese de polinucleotidos
|
|
DD133885B1
(de)
|
1978-01-04 |
1981-02-25 |
Hans Lehmann |
Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
|
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
|
US4542142A
(en)
|
1982-11-22 |
1985-09-17 |
Roussel Uclaf |
Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
|
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
|
US5118800A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
Oligonucleotides possessing a primary amino group in the terminal nucleotide
|
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
|
FR2567892B1
(fr)
|
1984-07-19 |
1989-02-17 |
Centre Nat Rech Scient |
Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
FR2576898B1
(fr)
|
1985-02-01 |
1988-01-08 |
Lafon Labor |
Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
|
|
US4659774A
(en)
|
1985-11-01 |
1987-04-21 |
American Hoechst Corporation |
Support for solid-phase oligonucleotide synthesis
|
|
US4840956A
(en)
|
1986-02-18 |
1989-06-20 |
Warner-Lambert Company |
Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
|
|
US4735949A
(en)
|
1986-02-18 |
1988-04-05 |
Warner-Lambert Company |
Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
|
|
IL83663A0
(en)
|
1986-10-27 |
1988-01-31 |
Robins Co Inc A H |
Preparation of 3-pyrrolidinols
|
|
EP0366685B1
(en)
|
1987-06-24 |
1994-10-19 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
DE3884517T2
(de)
|
1987-07-30 |
1994-02-10 |
Kupat Holim Health Insurance |
Biologisch aktive Carbonsäureester.
|
|
US4923901A
(en)
|
1987-09-04 |
1990-05-08 |
Millipore Corporation |
Membranes with bound oligonucleotides and peptides
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US4945158A
(en)
|
1988-08-12 |
1990-07-31 |
American Cyanamid Company |
Antidiabetic phosphonates
|
|
US4943629A
(en)
|
1988-08-12 |
1990-07-24 |
American Cyanamid Company |
Antidiabetic alpha-substituted phosphonates
|
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5141813A
(en)
|
1989-08-28 |
1992-08-25 |
Clontech Laboratories, Inc. |
Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
CA2029273A1
(en)
|
1989-12-04 |
1991-06-05 |
Christine L. Brakel |
Modified nucleotide compounds
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
CA2071897A1
(en)
|
1989-12-28 |
1991-06-29 |
Richard A. Glennon |
Sigma receptor ligands and the use thereof
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5506212A
(en)
|
1990-01-11 |
1996-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides with substantially chirally pure phosphorothioate linkages
|
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
|
US5457191A
(en)
|
1990-01-11 |
1995-10-10 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5620963A
(en)
|
1991-10-15 |
1997-04-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
|
|
AU651569B2
(en)
|
1990-01-11 |
1994-07-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for detecting and modulating RNA activity and gene expression
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
|
US5635488A
(en)
|
1991-10-15 |
1997-06-03 |
Isis Pharmaceuticals, Inc. |
Compounds having phosphorodithioate linkages of high chiral purity
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US5036964A
(en)
|
1990-03-28 |
1991-08-06 |
Dana Corporation |
Armature assembly for an electromagnetic coupling
|
|
US5292875A
(en)
|
1990-04-20 |
1994-03-08 |
Lynx Therapeutics, Inc. |
Method of synthesizing sulfurized oligonucleotide analogs
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
HUT63568A
(en)
|
1990-05-23 |
1993-09-28 |
Isis Pharmaceuticals Inc |
Composition and process for controlling the activity of rna by modifying the rna 5' cap structure
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
|
US5792844A
(en)
|
1990-07-27 |
1998-08-11 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent nitrogen atoms
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5223618A
(en)
|
1990-08-13 |
1993-06-29 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analog compounds
|
|
US6121433A
(en)
|
1990-07-27 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having nitrogen-containing linkages
|
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
|
US5998603A
(en)
|
1994-09-29 |
1999-12-07 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analogs, and oligomers thereof
|
|
US6087482A
(en)
|
1990-07-27 |
2000-07-11 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
US5783682A
(en)
|
1990-07-27 |
1998-07-21 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide mimics having nitrogen-containing linkages
|
|
WO1994022886A1
(en)
|
1993-03-30 |
1994-10-13 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5834607A
(en)
|
1990-07-27 |
1998-11-10 |
Isis Pharmaceuticals, Inc. |
Amines and methods of making and using the same
|
|
EP0544824B1
(en)
|
1990-07-27 |
1997-06-11 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US20020183502A1
(en)
|
1991-05-21 |
2002-12-05 |
Mesmaeker Alain De |
Backbone-modified oligonucleotide analogs and methods for using same
|
|
US6414112B1
(en)
|
1991-05-24 |
2002-07-02 |
Ole Buchardt |
Peptide nucleic acids having 2,6-diaminopurine nucleobases
|
|
BR9206131A
(pt)
|
1991-06-10 |
1995-05-02 |
Lucky Ltd |
Hepatite C: diagnóstico e vacinas
|
|
US5359052A
(en)
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
|
US5646267A
(en)
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
|
ATE221127T1
(de)
|
1991-10-15 |
2002-08-15 |
Isis Pharmaceuticals Inc |
Über chirale phosphoratome gebundene oligonukleotide
|
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5654284A
(en)
|
1991-10-15 |
1997-08-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
|
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
|
ES2103918T3
(es)
|
1991-10-17 |
1997-10-01 |
Ciba Geigy Ag |
Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
EP1044987B1
(en)
|
1991-12-24 |
2006-02-15 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
|
GB9213601D0
(en)
|
1992-06-26 |
1992-08-12 |
Mastico Robert A |
Protein based delivery system
|
|
US7067497B2
(en)
|
1992-09-29 |
2006-06-27 |
Isis Pharmaceuticals, Inc. |
Modulation of telomere length by oligonucleotides having a G-core sequence
|
|
US6005107A
(en)
|
1992-12-23 |
1999-12-21 |
Biochem Pharma, Inc. |
Antiviral compounds
|
|
US6444656B1
(en)
|
1992-12-23 |
2002-09-03 |
Biochem Pharma, Inc. |
Antiviral phosphonate nucleotides
|
|
AU6165494A
(en)
|
1993-01-25 |
1994-08-15 |
Hybridon, Inc. |
Oligonucleotide alkylphosphonates and alkylphosphonothioates
|
|
HU9501994D0
(en)
|
1993-03-31 |
1995-09-28 |
Sterling Winthrop Inc |
Novel 5'-substituted nucleosides and oligomers produced therefrom
|
|
CA2159628A1
(en)
|
1993-03-31 |
1994-10-13 |
Prasad Venkata Chala Chaturvedula |
Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
|
|
WO1998053801A1
(en)
|
1997-05-28 |
1998-12-03 |
Isis Pharmaceuticals, Inc. |
Conjugated peptide nucleic acids having enhanced cellular uptake
|
|
US5955591A
(en)
|
1993-05-12 |
1999-09-21 |
Imbach; Jean-Louis |
Phosphotriester oligonucleotides, amidites and method of preparation
|
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
DE69412704T2
(de)
|
1993-06-10 |
1999-02-04 |
Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo |
Spritzgiessform
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5643989A
(en)
|
1993-10-29 |
1997-07-01 |
Azdel, Inc. |
Fiber reinforced functionalized polyolefin composites
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
DE4435728A1
(de)
|
1994-01-19 |
1995-07-20 |
Boehringer Mannheim Gmbh |
Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
|
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
|
WO1995022615A1
(en)
|
1994-02-22 |
1995-08-24 |
Novo Nordisk A/S |
A method of preparing a variant of a lipolytic enzyme
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
HUT75368A
(en)
|
1994-05-11 |
1997-05-28 |
Novo Nordisk As |
An enzyme with endo-1,3(4)-beta-glucanase activity
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
DK0685475T3
(da)
|
1994-05-31 |
1999-08-30 |
Bayer Ag |
Amino-benzofuryl- og thienylderivater
|
|
HRP950288A2
(en)
|
1994-05-31 |
1997-08-31 |
Bayer Ag |
Oxalylamino-benzofuran- and benzothienyl-derivatives
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
DE69535905D1
(de)
|
1994-07-15 |
2009-02-26 |
Coley Pharm Group Inc |
Immunomodulatorische Oligonukleotide
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
AU3675195A
(en)
|
1994-09-07 |
1996-03-27 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
|
AU4514696A
(en)
|
1994-12-22 |
1996-07-10 |
Hybridon, Inc. |
Synthesis of stereospecific oligonucleotide phosphorothioates
|
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
|
ATE327244T1
(de)
|
1995-03-06 |
2006-06-15 |
Isis Pharmaceuticals Inc |
Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
EP0739983B1
(en)
|
1995-04-27 |
2009-12-30 |
Takara Bio Inc. |
Gene encoding lacto-n-biosidase
|
|
ES2220929T3
(es)
|
1995-05-11 |
2004-12-16 |
Applied Research Systems Ars Holding N.V. |
Inhibidor de la actividad il-6.
|
|
AU5855296A
(en)
|
1995-05-19 |
1996-11-29 |
Glycomed Incorporated |
Collection of activated glycoside compounds and their biolog ical use
|
|
DK0836612T3
(da)
|
1995-05-23 |
2000-10-30 |
Hybridon Inc |
Nye synthoner til stereoselektiv oligonucleotidsyntese
|
|
AU5871196A
(en)
|
1995-05-23 |
1996-12-24 |
Hybridon, Inc. |
Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
|
|
EP0831854A4
(en)
|
1995-06-06 |
2001-01-24 |
Isis Pharmaceuticals Inc |
OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
|
|
US5932450A
(en)
|
1995-06-07 |
1999-08-03 |
Gen-Probe Incorporated |
Enzymatic synthesis of oligonucleotides using digestible templates
|
|
DE69636649T2
(de)
|
1995-06-29 |
2007-10-04 |
Takara Bio Inc., Otsu |
Für einen Endoglycoceramidase-Aktivator kodierendes Gen
|
|
US5795765A
(en)
|
1995-06-29 |
1998-08-18 |
Takara Shuzo Co., Ltd. |
Gene encoding endoglycoceramidase
|
|
US6017700A
(en)
|
1995-08-04 |
2000-01-25 |
Bayer Corporation |
Cationic oligonucleotides, and related methods of synthesis and use
|
|
US5936080A
(en)
|
1996-05-24 |
1999-08-10 |
Genta Incorporated |
Compositions and methods for the synthesis of organophosphorus derivatives
|
|
WO1997009443A1
(en)
|
1995-09-05 |
1997-03-13 |
Michigan State University |
PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
US6160109A
(en)
|
1995-10-20 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Preparation of phosphorothioate and boranophosphate oligomers
|
|
US6476216B1
(en)
|
1995-10-20 |
2002-11-05 |
Mcgill University |
Preparation of phosphorothioate oligomers
|
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
|
JP2000506384A
(ja)
|
1996-02-15 |
2000-05-30 |
ナショナル インスティチューツ オブ ヘルス |
ＲＮａｓｅ Ｌ アクチベーター及びＲＳＶ感染の治療に有効なアンチセンスオリゴヌクレオチド
|
|
US6214805B1
(en)
|
1996-02-15 |
2001-04-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
RNase L activators and antisense oligonucleotides effective to treat RSV infections
|
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
|
US5824669A
(en)
|
1996-03-22 |
1998-10-20 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
|
|
DE69738254T2
(de)
|
1996-05-10 |
2008-08-14 |
Novozymes A/S |
Methode zur bereitstellung von dna sequenzen
|
|
US5856465A
(en)
|
1996-05-24 |
1999-01-05 |
Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych |
Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
DE19622783A1
(de)
|
1996-06-07 |
1997-12-11 |
Hoechst Ag |
Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
|
|
US6130038A
(en)
|
1996-07-16 |
2000-10-10 |
Gen-Probe Incorporated |
Method for amplifying target nucleic acids using modified primers
|
|
JP3306073B2
(ja)
|
1996-07-24 |
2002-07-24 |
ブヒャルト，ドルテ |
増加した結合親和性、配列特異性および溶解性を有するペプチド核酸
|
|
AU4156197A
(en)
|
1996-08-21 |
1998-03-06 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
GB9621522D0
(en)
|
1996-10-16 |
1996-12-04 |
Biocompatibles Ltd |
Synthesis of phosphorus compounds
|
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
|
US6639062B2
(en)
|
1997-02-14 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
|
|
US6369237B1
(en)
|
1997-03-07 |
2002-04-09 |
President And Fellows Of Harvard College |
DNA glycosylase inhibitors, and uses related thereto
|
|
US6015887A
(en)
|
1997-04-11 |
2000-01-18 |
Isis Pharmaceuticals, Inc. |
Chiral peptide nucleic acids and methods for preparing same
|
|
US6468983B2
(en)
|
1997-04-21 |
2002-10-22 |
The Cleveland Clinic Foundation |
RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
|
|
PL184612B1
(pl)
|
1997-04-25 |
2002-11-29 |
Pan |
Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
|
|
CN1268127A
(zh)
|
1997-06-27 |
2000-09-27 |
普罗格特-甘布尔公司 |
环状缩醛香料前体
|
|
WO1999005160A2
(en)
|
1997-07-25 |
1999-02-04 |
Hybridon, Inc. |
Oligonuclotides having 3' terminal stereospecific phosphorothioates
|
|
GB9717158D0
(en)
|
1997-08-13 |
1997-10-22 |
King S College London |
Solution synthesis of oligonucleotides and their phosphorothioate analogues
|
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
|
US6750344B1
(en)
|
1997-09-05 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Amine compounds and combinatorial libraries comprising same
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
DE19741715A1
(de)
|
1997-09-22 |
1999-03-25 |
Hoechst Ag |
Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
|
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
|
US6528640B1
(en)
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
|
US6080543A
(en)
|
1997-12-08 |
2000-06-27 |
E. & J. Gallo Winery |
Detection of fungal pathogens
|
|
US6582936B1
(en)
|
1997-12-12 |
2003-06-24 |
The Regents Of The University Of California |
Methods for making nucleic acids
|
|
US6248519B1
(en)
|
1998-03-11 |
2001-06-19 |
E & J Gallo Winery |
Detection of fermentation-related microorganisms
|
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
|
EP1077708A1
(en)
|
1998-05-06 |
2001-02-28 |
University Of Iowa Research Foundation |
Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
|
|
CA2328406A1
(en)
|
1998-05-14 |
1999-11-18 |
Hermann Wagner |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
WO2000006588A1
(en)
|
1998-07-27 |
2000-02-10 |
University Of Iowa Research Foundation |
STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
|
|
CA2340174C
(en)
|
1998-08-10 |
2011-01-04 |
Antigenics Llc |
Compositions of cpg and saponin adjuvants and methods thereof
|
|
WO2000023444A1
(en)
|
1998-10-21 |
2000-04-27 |
Abbott Laboratories |
5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
|
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
|
US6451524B1
(en)
|
1998-11-25 |
2002-09-17 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
|
AU1742600A
(en)
|
1998-11-25 |
2000-06-13 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
|
WO2000040749A2
(en)
|
1999-01-06 |
2000-07-13 |
Genenews Inc. |
Method for the detection of gene transcripts in blood and uses thereof
|
|
US6265172B1
(en)
|
1999-02-08 |
2001-07-24 |
University Of Kentucky |
Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
|
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
|
US6506594B1
(en)
|
1999-03-19 |
2003-01-14 |
Cornell Res Foundation Inc |
Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
|
|
GB9907245D0
(en)
|
1999-03-29 |
1999-05-26 |
Goldsborough Andrew |
Cleavage of nucleic acids from solid supports
|
|
JP3072345B1
(ja)
|
1999-03-31 |
2000-07-31 |
農林水産省家畜衛生試験場長 |
豚丹毒菌の組換えサブユニットワクチン
|
|
US5998148A
(en)
|
1999-04-08 |
1999-12-07 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microtubule-associated protein 4 expression
|
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
US6300069B1
(en)
|
1999-05-03 |
2001-10-09 |
Qiagen Gmbh |
Generation and amplification of nucleic acids from ribonucleic acids
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
US6066500A
(en)
|
1999-06-25 |
2000-05-23 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Beta catenin expression
|
|
US6271004B1
(en)
|
1999-06-25 |
2001-08-07 |
Display Systems Biotech A/S |
Method for improved reverse transcription at high temperatures
|
|
US6414135B1
(en)
|
1999-07-07 |
2002-07-02 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate monomers and related compounds
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
|
US7264932B2
(en)
|
1999-09-24 |
2007-09-04 |
Applera Corporation |
Nuclease inhibitor cocktail
|
|
TR200200797T2
(tr)
|
1999-09-25 |
2002-10-21 |
University Of Iowa Research Foundation |
İmmünostimülatör nükleik asitler
|
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
NZ517928A
(en)
|
1999-09-27 |
2004-09-24 |
Coley Pharm Gmbh |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
US20020082227A1
(en)
|
1999-09-30 |
2002-06-27 |
Scott Henry |
Use of oligonucleotides for inhibition of complement activation
|
|
WO2001025488A2
(en)
|
1999-10-06 |
2001-04-12 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger rna
|
|
GB9924285D0
(en)
|
1999-10-14 |
1999-12-15 |
Avecia Ltd |
Process
|
|
US20010055761A1
(en)
|
1999-10-29 |
2001-12-27 |
Agilent Technologies |
Small scale dna synthesis using polymeric solid support with functionalized regions
|
|
FR2800750B1
(fr)
|
1999-11-05 |
2003-01-31 |
Centre Nat Rech Scient |
Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
|
|
AU1656601A
(en)
|
1999-11-12 |
2001-06-12 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6322985B1
(en)
|
1999-12-27 |
2001-11-27 |
Technion Research And Development Foundation Ltd. |
Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
|
|
AU2743801A
(en)
|
1999-12-30 |
2001-07-16 |
Cabot Corporation |
Sensors with improved properties
|
|
WO2001050349A1
(en)
|
1999-12-30 |
2001-07-12 |
Rutgers, The State University Of New Jersey |
Electronic document customization and transformation utilizing user feedback
|
|
US6649750B1
(en)
|
2000-01-05 |
2003-11-18 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotide compounds
|
|
US6159697A
(en)
|
2000-01-19 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad7 expression
|
|
US7585847B2
(en)
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
|
GB0004889D0
(en)
|
2000-03-01 |
2000-04-19 |
Avecia Ltd |
Synthesis of oligonucleotides
|
|
CA2335389A1
(en)
|
2000-03-01 |
2001-09-01 |
Message Pharmaceuticals, Inc. |
Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
|
|
WO2001070663A2
(en)
|
2000-03-17 |
2001-09-27 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
|
DE10019756A1
(de)
|
2000-04-20 |
2001-10-25 |
Bayer Ag |
Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
|
|
CN1178911C
(zh)
|
2000-04-20 |
2004-12-08 |
弗·哈夫曼-拉罗切有限公司 |
吡咯烷与哌啶衍生物和它们用于治疗神经变性疾病的用途
|
|
AU2001259706A1
(en)
|
2000-05-09 |
2001-11-20 |
Reliable Biopharmaceutical, Inc. |
Polymeric compounds useful as prodrugs
|
|
US6492171B2
(en)
|
2000-05-16 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of TERT expression
|
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
|
AU2001278517A1
(en)
|
2000-08-03 |
2002-02-18 |
F. Hoffman-La Roche Ag |
Nucleic acid binding compounds containing pyrazolo(3,4-d)pyrimidine analogues of purin-2,6-diamine and their uses
|
|
US6725412B1
(en)
|
2000-08-15 |
2004-04-20 |
Dolby Laboratories Licensing Corporation |
Low latency data encoder
|
|
US6809195B1
(en)
|
2000-08-16 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotides
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
CA2419894A1
(en)
|
2000-09-15 |
2002-03-21 |
Coley Pharmaceutical Gmbh |
Process for high throughput screening of cpg-based immuno-agonist/antagonist
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
GB0024752D0
(en)
|
2000-10-10 |
2000-11-22 |
Univ Belfast |
Oxidative halogenation of aromatic compounds
|
|
BR0114786A
(pt)
|
2000-10-18 |
2003-08-12 |
Glaxosmithkline Biolog Sa |
Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
|
|
US6372492B1
(en)
|
2000-10-30 |
2002-04-16 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of talin expression
|
|
US6682889B1
(en)
|
2000-11-08 |
2004-01-27 |
Becton, Dickinson And Company |
Amplification and detection of organisms of the Chlamydiaceae family
|
|
NL1016978C2
(nl)
|
2000-12-22 |
2002-06-25 |
Robert Jan Colenbrander |
Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
|
|
DZ3487A1
(fr)
|
2001-01-22 |
2002-07-25 |
Merck Sharp & Dohme |
Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
|
|
US8008459B2
(en)
|
2001-01-25 |
2011-08-30 |
Evolva Sa |
Concatemers of differentially expressed multiple genes
|
|
DK1356037T3
(da)
|
2001-01-25 |
2011-06-27 |
Evolva Ltd |
Bibliotek med en samling af celler
|
|
AU2002224668B2
(en)
|
2001-01-26 |
2007-09-20 |
Commonwealth Scientific And Industrial Research Organisation |
Methods and means for producing efficient silencing construct using recombinational cloning
|
|
US20050277133A1
(en)
|
2001-05-18 |
2005-12-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
|
WO2002097134A2
(en)
|
2001-05-25 |
2002-12-05 |
Isis Pharmaceuticals, Inc. |
Modified peptide nucleic acid
|
|
GB0113523D0
(en)
|
2001-06-04 |
2001-07-25 |
Torotrak Dev Ltd |
An Hydraulic control circuit for a continuosly variable transmission
|
|
US20030069410A1
(en)
*
|
2001-06-14 |
2003-04-10 |
Isis Pharmaceuticals, Inc. |
Methods for preparing oligonucleotides having chiral phosphorothioate linkages
|
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
AU2002322358B2
(en)
|
2001-06-29 |
2009-06-18 |
Novartis Vaccines And Diagnostics, Inc. |
HCV E1E2 vaccine compositions
|
|
CA2452458A1
(en)
|
2001-07-03 |
2003-01-16 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
|
US7205399B1
(en)
|
2001-07-06 |
2007-04-17 |
Sirna Therapeutics, Inc. |
Methods and reagents for oligonucleotide synthesis
|
|
US6440739B1
(en)
|
2001-07-17 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of glioma-associated oncogene-2 expression
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US6455308B1
(en)
|
2001-08-01 |
2002-09-24 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of serum amyloid A4 expression
|
|
US7888324B2
(en)
|
2001-08-01 |
2011-02-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
|
AU2002361468A1
(en)
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
|
EP1418877A2
(en)
|
2001-08-24 |
2004-05-19 |
Massachusetts Institute Of Technology |
Reagents that facilitate the purification of compounds synthesized on a solid support
|
|
US7049122B2
(en)
|
2001-09-21 |
2006-05-23 |
Academia Sinica |
Mutant-type lipases and applications thereof
|
|
US6933288B2
(en)
|
2002-02-04 |
2005-08-23 |
Isis Pharmaceuticals, Inc. |
Pyranosyl cytosines: pharmaceutical formulations and methods
|
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
|
US20040149587A1
(en)
|
2002-02-15 |
2004-08-05 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
|
US20030159938A1
(en)
|
2002-02-15 |
2003-08-28 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
|
US20050096284A1
(en)
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US20040023901A1
(en)
|
2002-02-28 |
2004-02-05 |
Cook Phillip D. |
Nucleoside 5'-monophosphate mimics and their prodrugs
|
|
EP1485395A4
(en)
|
2002-02-28 |
2011-04-13 |
Biota Scient Management |
NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
|
|
US7288376B2
(en)
|
2002-03-22 |
2007-10-30 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
|
|
US20040102394A1
(en)
|
2002-11-23 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of huntingtin interacting protein 2 expression
|
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
|
AU2003237875A1
(en)
|
2002-05-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
|
AU2003241621A1
(en)
|
2002-05-24 |
2003-12-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
|
WO2003099840A1
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
|
AU2003248708A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
|
PL375306A1
(en)
|
2002-06-20 |
2005-11-28 |
Cytos Biotechnology Ag |
Packaged virus-like particles for use as adjuvants: method of preparation and use
|
|
WO2004003228A1
(en)
|
2002-07-01 |
2004-01-08 |
Unisearch Limited |
Genotyping method
|
|
US8101348B2
(en)
|
2002-07-10 |
2012-01-24 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
RNA-interference by single-stranded RNA molecules
|
|
US20040023905A1
(en)
|
2002-07-31 |
2004-02-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of LAR expression
|
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
|
US20050255086A1
(en)
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
|
WO2004014312A2
(en)
|
2002-08-08 |
2004-02-19 |
Sirna Therapeutics, Inc. |
Small-mer compositions and methods of use
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US7414116B2
(en)
|
2002-08-23 |
2008-08-19 |
Illumina Cambridge Limited |
Labelled nucleotides
|
|
AU2003267785C1
(en)
|
2002-09-13 |
2009-12-24 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
|
US7030230B2
(en)
|
2002-10-25 |
2006-04-18 |
Isis Pharmaceuticals, Inc. |
Process of purifying phosphoramidites
|
|
CN1753687A
(zh)
|
2002-10-29 |
2006-03-29 |
科勒制药集团股份有限公司 |
Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
|
|
WO2004044141A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Conjugated oligomeric compounds and their use in gene modulation
|
|
AU2003291721A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
|
EP1562971B1
(en)
|
2002-11-05 |
2014-02-12 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
AU2003295387A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
|
US7381527B2
(en)
|
2002-11-06 |
2008-06-03 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants
|
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質ｂ発現のアンチセンス調節
|
|
US8090542B2
(en)
|
2002-11-14 |
2012-01-03 |
Dharmacon Inc. |
Functional and hyperfunctional siRNA
|
|
AU2004220556B2
(en)
|
2003-03-07 |
2009-05-07 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
WO2004080466A1
(en)
|
2003-03-07 |
2004-09-23 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
GB0306657D0
(en)
|
2003-03-24 |
2003-04-30 |
Avecia Ltd |
Process and compounds
|
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
|
JP5022028B2
(ja)
|
2003-03-26 |
2012-09-12 |
サイトス・バイオテクノロジー・アクチェンゲゼルシャフト |
メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
|
US20090247488A1
(en)
|
2003-04-25 |
2009-10-01 |
Carina Cannizzaro |
Anti-inflammatory phosphonate compounds
|
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
|
CA2523083C
(en)
|
2003-04-25 |
2014-07-08 |
Gilead Sciences, Inc. |
Antiviral phosphonate analogs
|
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
|
WO2004096233A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates
|
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
|
BRPI0409680A
(pt)
|
2003-04-25 |
2006-04-18 |
Gilead Sciences Inc |
análogos de fosfonato anti-cáncer
|
|
CN101410120A
(zh)
|
2003-04-25 |
2009-04-15 |
吉里德科学公司 |
抗炎的膦酸酯化合物
|
|
US7045306B2
(en)
|
2003-04-28 |
2006-05-16 |
The General Hospital Corporation |
Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
|
|
US7214491B2
(en)
|
2003-05-07 |
2007-05-08 |
E. I. Du Pont De Nemours And Company |
Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
|
|
AU2004239114B2
(en)
|
2003-05-14 |
2008-03-13 |
Japan Science And Technology Agency |
Inhibition of the expression of huntingtin gene
|
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
|
EA200600069A1
(ru)
|
2003-06-20 |
2006-08-25 |
Коли Фармасьютикал Гмбх |
Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
|
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
|
JP2011088935A
(ja)
|
2003-08-08 |
2011-05-06 |
Chiralgen Ltd |
リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド３’−ホスホロアミダイト
|
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
WO2005019237A1
(en)
|
2003-08-21 |
2005-03-03 |
Griffith University |
Novel sulfenamides
|
|
RU2006108577A
(ru)
|
2003-08-21 |
2007-09-27 |
Гриффит Юниверсити (Au) |
Новые сульфенамиды
|
|
WO2005021568A2
(en)
|
2003-08-27 |
2005-03-10 |
Biota, Inc. |
Novel tricyclic nucleosides or nucleotides as therapeutic agents
|
|
DK1661905T3
(da)
|
2003-08-28 |
2012-07-23 |
Takeshi Imanishi |
Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
|
|
JP4616175B2
(ja)
|
2003-09-02 |
2011-01-19 |
株式会社キラルジェン |
５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
|
|
JP4580870B2
(ja)
|
2003-09-02 |
2010-11-17 |
株式会社キラルジェン |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
|
KR101298493B1
(ko)
|
2003-09-09 |
2013-08-21 |
제론 코포레이션 |
텔로머라제 억제를 위한 변형 올리고뉴클레오티드
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
|
ES2485848T3
(es)
|
2003-09-12 |
2014-08-14 |
University Of Massachusetts |
ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
WO2008005562A2
(en)
|
2006-07-07 |
2008-01-10 |
University Of Massachusetts |
Rna silencing compositions and methods for the treatment of huntington's disease
|
|
GB0323968D0
(en)
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
|
SG122973A1
(en)
|
2003-10-30 |
2006-06-29 |
Coley Pharm Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
|
US20050239102A1
(en)
|
2003-10-31 |
2005-10-27 |
Verdine Gregory L |
Nucleic acid binding oligonucleotides
|
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
|
WO2005063983A1
(en)
|
2003-12-29 |
2005-07-14 |
Galapagos Genomics N.V. |
Modulators of bone homeostasis identified in a high-throughput screen
|
|
WO2005070859A1
(ja)
|
2004-01-27 |
2005-08-04 |
Takeshi Wada |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
US20050176045A1
(en)
|
2004-02-06 |
2005-08-11 |
Dharmacon, Inc. |
SNP discriminatory siRNA
|
|
WO2005076744A2
(en)
|
2004-02-18 |
2005-08-25 |
Frutarom Ltd. |
Method for the preparation of peptide-oligonucleotide conjugates
|
|
JP3976742B2
(ja)
|
2004-02-27 |
2007-09-19 |
江守商事株式会社 |
インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
|
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
JP4865544B2
(ja)
|
2004-03-25 |
2012-02-01 |
株式会社キラルジェン |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
JP2007531794A
(ja)
|
2004-04-05 |
2007-11-08 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
|
|
TWI350168B
(en)
|
2004-05-07 |
2011-10-11 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals
|
|
WO2005116268A2
(en)
|
2004-05-27 |
2005-12-08 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health |
Differential expression of molecules associated with acute stroke
|
|
US7759318B1
(en)
|
2004-05-28 |
2010-07-20 |
Isis Pharmaceuticals, Inc. |
Identification of novel pathways, genes and promoter motifs regulating adipogenesis
|
|
CA2569419A1
(en)
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
SI2206781T1
(sl)
|
2004-06-28 |
2016-05-31 |
The University Of Western Australia |
Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
|
|
PT2409713E
(pt)
|
2004-08-10 |
2015-10-09 |
Genzyme Corp |
Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos
|
|
CA2577922C
(en)
|
2004-08-26 |
2013-06-25 |
Nippon Shinyaku Co., Ltd. |
Phosphoramidite compound and method for producing oligo-rna
|
|
CA2578046A1
(en)
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
WO2006031461A2
(en)
|
2004-09-09 |
2006-03-23 |
Isis Pharmaceuticals, Inc. |
Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
|
|
EP2397563A3
(en)
|
2004-09-17 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
|
CA2582464A1
(en)
|
2004-10-13 |
2006-04-27 |
Sanjay Bhanot |
Antisense modulation of ptp1b expression
|
|
CA2585091C
(en)
|
2004-11-03 |
2016-07-19 |
University Of Kansas |
Novobiocin analogues as anticancer agents
|
|
US8212011B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues
|
|
US7622451B2
(en)
|
2004-11-03 |
2009-11-24 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
|
US8212012B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
|
KR100721928B1
(ko)
|
2004-11-05 |
2007-05-28 |
주식회사 바이오씨에스 |
ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
|
|
EP1657307A1
(en)
|
2004-11-16 |
2006-05-17 |
Immunotech S.A. |
Oligonucleotides that induce the secretion of GM-CSF
|
|
AU2005313883B2
(en)
|
2004-12-09 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
US9809824B2
(en)
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
WO2006066260A2
(en)
|
2004-12-17 |
2006-06-22 |
Thiosense, Inc. |
Compositions of and methods for producing phosphorus-chiral monomers and oligomers
|
|
US20070099851A1
(en)
|
2004-12-30 |
2007-05-03 |
Linn Gregory S |
Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
|
|
US20060183763A1
(en)
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
|
EP1841777B1
(en)
|
2005-01-28 |
2015-09-30 |
Kwon, Hyung-Joo |
Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
|
|
CN101160401A
(zh)
|
2005-02-24 |
2008-04-09 |
科勒制药集团公司 |
免疫刺激寡核苷酸
|
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
NZ562954A
(en)
|
2005-05-05 |
2009-10-30 |
Antisense Pharma Gmbh |
Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors
|
|
US20060257912A1
(en)
|
2005-05-06 |
2006-11-16 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
|
US8361977B2
(en)
|
2005-06-23 |
2013-01-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of SMN2 splicing
|
|
EP2316967A1
(en)
|
2005-06-28 |
2011-05-04 |
Medtronic, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin gene.
|
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
|
EP1948600B1
(en)
|
2005-07-05 |
2014-04-16 |
The President & Fellows Of Harvard College |
Liver targeted conjugates
|
|
JP4984634B2
(ja)
|
2005-07-21 |
2012-07-25 |
ソニー株式会社 |
物理情報取得方法および物理情報取得装置
|
|
US8632963B2
(en)
|
2005-07-28 |
2014-01-21 |
Id-Fish Technology Inc. |
Method for improving cell permeability to foreign particles
|
|
JP5523705B2
(ja)
|
2005-08-29 |
2014-06-18 |
レグルス・セラピューティクス・インコーポレイテッド |
Ｍｉｒ−１２２ａをモジュレートする使用方法
|
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US20070077993A1
(en)
|
2005-09-30 |
2007-04-05 |
Midgley Timothy M |
Method and apparatus for collecting user game play data and crediting users in a gaming environment
|
|
EP2341059A1
(en)
|
2005-10-12 |
2011-07-06 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
|
|
US9308252B2
(en)
|
2005-10-27 |
2016-04-12 |
Cook Biotech, Inc. |
Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
|
|
CN101365801B
(zh)
|
2005-10-28 |
2013-03-27 |
阿尔尼拉姆医药品有限公司 |
抑制亨廷顿基因表达的组合物和方法
|
|
CN101466834B
(zh)
|
2005-10-28 |
2013-09-25 |
东曹株式会社 |
制备类胡萝卜素合成性微生物的方法和生产类胡萝卜素的方法
|
|
WO2007059041A2
(en)
|
2005-11-11 |
2007-05-24 |
Pfizer, Inc. |
Combinations and methods of using an immunomodulatory oligodeoxynucleotide
|
|
WO2007064291A1
(en)
|
2005-11-30 |
2007-06-07 |
Jyoti Chattopadhyaya |
Method and compounds for rna synthesis
|
|
ES2707787T3
(es)
|
2005-12-02 |
2019-04-05 |
Ionis Pharmaceuticals Inc |
Análogos antibacterianos de aminoglucósido 4,5-sustituidos que tienen sustituyentes múltiples
|
|
US8076303B2
(en)
|
2005-12-13 |
2011-12-13 |
Spring Bank Pharmaceuticals, Inc. |
Nucleotide and oligonucleotide prodrugs
|
|
MEP0808A
(xx)
|
2005-12-21 |
2010-02-10 |
Pfizer Prod Inc |
Karbonilamino pirolopirayoli, snažni inhibitori kinaza
|
|
JP5425474B2
(ja)
|
2006-01-26 |
2014-02-26 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
ハンチンチン対する、組成物及びその使用
|
|
CA2640171C
(en)
|
2006-01-27 |
2014-10-28 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
|
DK1991678T4
(da)
|
2006-02-15 |
2020-10-19 |
Rechtsanwalt Thomas Beck |
Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
|
|
JP4713514B2
(ja)
|
2006-02-20 |
2011-06-29 |
エフ．ホフマン−ラ ロシュ アーゲー |
改善された標識試薬
|
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
CA2647827A1
(en)
|
2006-03-31 |
2007-10-11 |
Applied Biosystems Inc. |
Reagents useful for synthesizing rhodamine-labeled oligonucleotides
|
|
US8088582B2
(en)
|
2006-04-06 |
2012-01-03 |
Ibis Biosciences, Inc. |
Compositions for the use in identification of fungi
|
|
BRPI0710512A2
(pt)
|
2006-04-20 |
2012-06-05 |
Hoffmann La Roche |
moduladores derivados de diazepan de receptores de quimiocinas
|
|
CN101432440B
(zh)
|
2006-04-24 |
2013-08-21 |
西格马食品可变资本有限公司 |
通过实时聚合酶链反应检测和多重、同时量化病原体的方法
|
|
US20100008937A1
(en)
|
2006-04-25 |
2010-01-14 |
Immune Disease Institute, Inc. |
Targeted delivery to leukocytes using non-protein carriers
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
CA3044969A1
(en)
|
2006-05-05 |
2007-12-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gene expression
|
|
US8158598B2
(en)
|
2006-05-05 |
2012-04-17 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to PTPR alpha
|
|
US20090012120A1
(en)
|
2006-05-10 |
2009-01-08 |
Board Of Trustees Of Michigan State University |
Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
JP5441688B2
(ja)
|
2006-05-11 |
2014-03-12 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
５’修飾二環式核酸類似体
|
|
ES2389112T3
(es)
|
2006-05-31 |
2012-10-23 |
Toray Industries, Inc. |
Oligonucleótido inmunoestimulador y aplicación farmacéutica del mismo
|
|
US8097596B2
(en)
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
|
JP6125741B2
(ja)
|
2006-07-12 |
2017-05-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達
|
|
US7666888B2
(en)
|
2006-07-20 |
2010-02-23 |
Amgen Inc. |
Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
|
|
GB0614947D0
(en)
|
2006-07-27 |
2006-09-06 |
Isis Innovation |
Epitope reduction therapy
|
|
US8101585B2
(en)
|
2006-08-04 |
2012-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of JNK proteins
|
|
AT504194B1
(de)
|
2006-09-07 |
2008-07-15 |
Oesterr Rotes Kreuz |
Bakteriennachweis
|
|
US8138330B2
(en)
|
2006-09-11 |
2012-03-20 |
Sigma-Aldrich Co. Llc |
Process for the synthesis of oligonucleotides
|
|
KR101251707B1
(ko)
|
2006-09-27 |
2013-04-11 |
콜리 파마슈티칼 게엠베하 |
면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
|
|
DK2092065T4
(da)
|
2006-10-18 |
2019-10-21 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser
|
|
CN101589047A
(zh)
|
2006-10-23 |
2009-11-25 |
Irm责任有限公司 |
组织蛋白酶类抑制剂
|
|
RU2009115687A
(ru)
|
2006-10-26 |
2010-11-10 |
Коли Фармасьютикал Гмбх (De) |
Олигорибонуклеотиды и их применения
|
|
FR2908414B1
(fr)
|
2006-11-13 |
2012-01-20 |
Centre Nat Rech Scient |
Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
|
|
US8754107B2
(en)
|
2006-11-17 |
2014-06-17 |
Abbvie Inc. |
Aminopyrrolidines as chemokine receptor antagonists
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
EP2453016A1
(en)
|
2006-11-27 |
2012-05-16 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
WO2008073959A2
(en)
|
2006-12-12 |
2008-06-19 |
Idera Pharmaceuticals, Inc. |
Synthetic agonists of tlr9
|
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
WO2008101157A1
(en)
|
2007-02-15 |
2008-08-21 |
Isis Pharmaceuticals, Inc. |
5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
|
|
RU2559536C2
(ru)
|
2007-03-24 |
2015-08-10 |
Джензим Корпорейшн |
Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
|
|
US7960353B2
(en)
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
|
EP2158316B1
(en)
|
2007-05-11 |
2015-04-15 |
Adynxx, Inc. |
Gene expression and pain
|
|
US8222407B2
(en)
|
2007-05-24 |
2012-07-17 |
Kyorin Pharmaceutical Co., Ltd. |
Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
|
|
GB0710186D0
(en)
|
2007-05-29 |
2007-07-04 |
Texas Instr Denmark |
PWM loop with minimum allasing error property
|
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
US8188301B2
(en)
|
2007-06-05 |
2012-05-29 |
Nsab, Filial Af Neurosearch Sweden Ab, Sverige |
Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
|
|
ES2386492T3
(es)
|
2007-06-08 |
2012-08-21 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos carbocíclicos
|
|
WO2008151833A2
(en)
|
2007-06-13 |
2008-12-18 |
Hochschule Mannheim |
Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
|
|
DE602007005629D1
(de)
|
2007-06-18 |
2010-05-12 |
Commissariat Energie Atomique |
Reversibles siRNA-Silencing eines mutierten und endogenen Huntington-Wildtypgens und dessen Anwendung zur Behandlung von Morbus Huntington
|
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
|
CN101796062B
(zh)
|
2007-07-05 |
2014-07-30 |
Isis制药公司 |
6-双取代双环核酸类似物
|
|
JP5737937B2
(ja)
|
2007-07-09 |
2015-06-17 |
イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物
|
|
TWI413530B
(zh)
|
2007-07-20 |
2013-11-01 |
Kao Corp |
有機聚矽氧
|
|
CA2694718A1
(en)
|
2007-07-31 |
2009-02-05 |
University Of Saskatchewan |
Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
|
|
US7812003B2
(en)
|
2007-08-02 |
2010-10-12 |
Safe Stephen H |
Antisense microRNA and uses therefor
|
|
KR20100066512A
(ko)
|
2007-08-15 |
2010-06-17 |
이데라 파마슈티칼즈, 인코포레이티드 |
톨 유사 수용체 조절자
|
|
MX2010003606A
(es)
|
2007-10-01 |
2010-07-02 |
Isis Pharmaceuticals Inc |
Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
|
|
KR100886139B1
(ko)
|
2007-11-13 |
2009-02-27 |
주식회사 삼천리제약 |
올리고뉴클레오타이드의 제조방법
|
|
TW200930375A
(en)
|
2007-12-21 |
2009-07-16 |
Exelixis Inc |
Benzofuropyrimidinones
|
|
TWI340765B
(en)
|
2007-12-26 |
2011-04-21 |
Ind Tech Res Inst |
Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
|
|
US20100309376A1
(en)
|
2008-01-15 |
2010-12-09 |
Yungchun Lei |
Multimedia Presenting System, Multimedia Processing Apparatus Thereof, and Method for Presenting Video and Audio Signals
|
|
WO2009089659A1
(en)
|
2008-01-18 |
2009-07-23 |
Shanghai Targetdrug Co., Ltd. |
Pyrollidine-based compounds
|
|
US20110105587A1
(en)
|
2008-02-04 |
2011-05-05 |
David Frederik Fishcher |
Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
|
|
JP2009190983A
(ja)
|
2008-02-12 |
2009-08-27 |
Tokyo Institute Of Technology |
オリゴヌクレオチド誘導体
|
|
US8426378B2
(en)
|
2008-03-21 |
2013-04-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucelosides and methods for their use
|
|
WO2009142822A2
(en)
|
2008-03-26 |
2009-11-26 |
Alnylam Pharmaceuticals, Inc. |
2-f modified rna interference agents
|
|
CN102123716B
(zh)
|
2008-04-03 |
2013-09-18 |
春堤公司 |
用于治疗病毒感染的化合物和方法
|
|
WO2009121347A1
(de)
|
2008-04-04 |
2009-10-08 |
Universität Hamburg |
Verfahren zur stereoselektiven synthese von phosphorverbindungen
|
|
WO2009124238A1
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
|
WO2009135322A1
(en)
|
2008-05-09 |
2009-11-12 |
The Universtity Of British Columbia |
Methods and compositions for the treatment of huntington's disease
|
|
US8679750B2
(en)
|
2008-05-09 |
2014-03-25 |
The University Of British Columbia |
Methods and compositions for the treatment of Huntington'S disease
|
|
WO2009143391A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
|
US8541387B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Modulation of SMRT expression
|
|
WO2009143390A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of rbp4
|
|
WO2009148605A2
(en)
|
2008-06-04 |
2009-12-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
AU2009266806A1
(en)
|
2008-07-03 |
2010-01-07 |
Exelixis Inc. |
CDK modulators
|
|
WO2010030849A1
(en)
|
2008-09-12 |
2010-03-18 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for treating cancer,inhibiting proliferation, and inducing cell death
|
|
WO2010030858A1
(en)
|
2008-09-15 |
2010-03-18 |
Enanta Pharmaceuticals, Inc. |
4'-allene-substituted nucleoside derivatives
|
|
EP2346883B1
(en)
|
2008-09-23 |
2016-03-23 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
|
DK2356129T3
(da)
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
|
DK2361256T3
(da)
|
2008-09-24 |
2013-07-01 |
Isis Pharmaceuticals Inc |
Cyclohexenyl-nukleinsyreanaloger
|
|
EP2344204A4
(en)
|
2008-10-07 |
2012-07-04 |
Harvard College |
TELOMERASE INHIBITOR AND METHOD OF USE THEREOF
|
|
PL2350279T3
(pl)
|
2008-10-22 |
2016-05-31 |
Quark Pharmaceuticals Inc |
Sposoby leczenia chorób oczu
|
|
AU2009308217B2
(en)
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
US9394333B2
(en)
|
2008-12-02 |
2016-07-19 |
Wave Life Sciences Japan |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
CA2747999A1
(en)
|
2008-12-23 |
2010-07-01 |
Girindus America, Inc. |
Sulfurizing reagents and their use for oligonucleotides synthesis
|
|
WO2010080953A1
(en)
|
2009-01-08 |
2010-07-15 |
Isis Pharmaceuticals, Inc. |
Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
|
|
KR20100087540A
(ko)
|
2009-01-28 |
2010-08-05 |
삼성전자주식회사 |
잉크젯 기록용 잉크 조성물
|
|
WO2010091301A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and excipients
|
|
WO2010093705A2
(en)
|
2009-02-10 |
2010-08-19 |
Idera Pharmaceuticals, Inc. |
Synthetic rna-based agonists of tlr7
|
|
JP5766617B2
(ja)
|
2009-02-20 |
2015-08-19 |
ユニバーシティ・オブ・カンザス |
修飾された糖部分を有するノボビオシン類似体
|
|
WO2010101951A1
(en)
|
2009-03-02 |
2010-09-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
|
WO2010107838A1
(en)
|
2009-03-16 |
2010-09-23 |
Isis Pharmaceuticals, Inc. |
Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
|
|
WO2010113937A1
(ja)
|
2009-03-31 |
2010-10-07 |
武田薬品工業株式会社 |
ヌクレオシドの製造方法
|
|
US8987222B2
(en)
|
2009-04-08 |
2015-03-24 |
University Of Massachusetts |
Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
|
|
US20120156138A1
(en)
|
2009-04-14 |
2012-06-21 |
Smith Larry J |
Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
|
|
US9260493B2
(en)
|
2009-05-07 |
2016-02-16 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids using modified dsRNA binding domains
|
|
US20120142763A1
(en)
|
2009-06-01 |
2012-06-07 |
The Regents Of The University Of California |
Nucleic acid delivery compositions and methods of use thereof
|
|
HUE031051T2
(en)
|
2009-06-05 |
2017-06-28 |
Infectious Disease Res Inst |
Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
|
|
PT3449926T
(pt)
|
2009-06-17 |
2019-11-12 |
Cold Spring Harbor Laboratory |
Composições e métodos de modulação de excisões de smn2 em um sujeito
|
|
JP5670097B2
(ja)
|
2009-06-19 |
2015-02-18 |
花王株式会社 |
二層分離型毛髪化粧料
|
|
US20120108800A1
(en)
|
2009-06-23 |
2012-05-03 |
Shumpei Murata |
Method for synthesizing nucleic acid
|
|
US8329024B2
(en)
|
2009-07-06 |
2012-12-11 |
Ada Technologies, Inc. |
Electrochemical device and method for long-term measurement of hypohalites
|
|
MX342945B
(es)
|
2009-07-06 |
2016-10-18 |
Ontorii Inc * |
Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
|
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
|
WO2011005942A2
(en)
|
2009-07-08 |
2011-01-13 |
Idera Pharmaceuticals, Inc. |
Oligonucleotide-based compounds as inhibitors of toll-like receptors
|
|
WO2011010706A1
(ja)
|
2009-07-23 |
2011-01-27 |
武田薬品工業株式会社 |
Fgf21シスエレメント結合物質
|
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
|
UA107360C2
(en)
|
2009-08-05 |
2014-12-25 |
Biogen Idec Inc |
Bicyclic aryl sphingosine 1-phosphate analogs
|
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
US8927553B2
(en)
|
2009-08-10 |
2015-01-06 |
Daljit Singh Dhanoa |
Deuterium-enriched alkyl sulfonamides and uses thereof
|
|
NZ599032A
(en)
|
2009-09-11 |
2014-09-26 |
Isis Pharmaceuticals Inc |
Modulation of huntingtin expression
|
|
EP2479182B8
(en)
|
2009-09-16 |
2016-07-13 |
Wave Life Sciences Japan, Inc. |
Novel protecting group for synthesizing rna and derivative thereof
|
|
WO2011038288A1
(en)
|
2009-09-25 |
2011-03-31 |
Isis Pharmaceuticals, Inc. |
Modulation of ttc39 expression to increase hdl
|
|
EA201290147A1
(ru)
|
2009-10-15 |
2012-11-30 |
Пфайзер Инк. |
Пирроло[2,3-d]пиримидиновые соединения
|
|
TWI475051B
(zh)
|
2009-11-18 |
2015-03-01 |
花王股份有限公司 |
Organic polysiloxane
|
|
JP5809408B2
(ja)
|
2009-11-25 |
2015-11-10 |
花王株式会社 |
毛髪化粧料
|
|
WO2011075560A1
(en)
|
2009-12-17 |
2011-06-23 |
Merck Sharp & Dohme Corp. |
Aminopyrimidines as syk inhibitors
|
|
CA2782782A1
(en)
|
2009-12-28 |
2011-07-07 |
Achira Labs Pvt. Ltd. |
Diagnostic gel composition, method for making a diagnostic gel composition
|
|
EP2521556B1
(en)
|
2010-01-08 |
2018-05-30 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
US8750507B2
(en)
|
2010-01-25 |
2014-06-10 |
Cisco Technology, Inc. |
Dynamic group creation for managed key servers
|
|
WO2011097644A2
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
EP3561060A1
(en)
|
2010-02-08 |
2019-10-30 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
EA021048B1
(ru)
|
2010-02-10 |
2015-03-31 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
|
|
JP5847700B2
(ja)
|
2010-03-05 |
2016-01-27 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
リボヌクレオシドホスホロチオエートの製造方法
|
|
WO2011127175A1
(en)
|
2010-04-06 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cd130 (gp130) expression
|
|
JP2013527148A
(ja)
|
2010-04-07 |
2013-06-27 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｃｅｔｐ発現の調節
|
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
|
US9127033B2
(en)
|
2010-04-28 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
5′ modified nucleosides and oligomeric compounds prepared therefrom
|
|
EP2601204B1
(en)
|
2010-04-28 |
2016-09-07 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides and oligomeric compounds prepared therefrom
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
WO2011135396A1
(en)
|
2010-04-30 |
2011-11-03 |
Cellectis |
Method for modulating double-strand break-induced homologous recombination
|
|
GB201008902D0
(en)
|
2010-05-27 |
2010-07-14 |
Imp Innovations Ltd |
Membrane enhanced polymer sythesis
|
|
EP2611927B1
(en)
|
2010-08-31 |
2018-08-01 |
Sirna Therapeutics, Inc. |
Novel single chemical entities and methods for delivery of oligonucleotides
|
|
DK2620428T3
(da)
|
2010-09-24 |
2019-07-01 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
WO2012043633A1
(ja)
|
2010-09-30 |
2012-04-05 |
独立行政法人国立精神・神経医療研究センター |
優性変異遺伝子発現抑制剤
|
|
KR101381048B1
(ko)
|
2010-10-20 |
2014-04-14 |
씨제이제일제당 (주) |
Ｏ-포스포세린 생산 균주 및 이로부터 생산된 ｏ-포스포세린으로부터 ｌ-시스테인 또는 이의 유도체의 생산방법
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
WO2012073857A1
(ja)
|
2010-11-30 |
2012-06-07 |
株式会社キラルジェン |
２'－ｏ－修飾ｒｎａ
|
|
WO2012092367A1
(en)
|
2010-12-28 |
2012-07-05 |
University Of Rochester |
Nucleic acid binding compounds, methods of making, and use thereof
|
|
EP3467109A1
(en)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
ES2739804T3
(es)
|
2011-02-12 |
2020-02-04 |
Univ Iowa Res Found |
Compuestos terapéuticos
|
|
US9353371B2
(en)
|
2011-05-02 |
2016-05-31 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
AR088140A1
(es)
|
2011-07-19 |
2014-05-14 |
Univ Idaho |
Sonda y metodo para direccionar acidos nucleicos
|
|
EP2742056B2
(en)
|
2011-08-11 |
2020-06-10 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
US9282242B2
(en)
|
2011-08-24 |
2016-03-08 |
Htc Corporation |
Method and electric device for taking panoramic photograph
|
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
US20140080896A1
(en)
|
2011-08-30 |
2014-03-20 |
The Regents Of The University Of California |
Identification of small molecules that facilitate therapeutic exon skipping
|
|
EP3202914B2
(en)
|
2011-08-31 |
2023-06-28 |
The University of Manchester |
Method for treating a neurodegenerative disease
|
|
US20140255936A1
(en)
|
2011-09-09 |
2014-09-11 |
Mayo Foundation For Medical Education And Research |
Detecting frontotemporal dementia and amyotrophic lateral sclerosis
|
|
EP2785729B1
(en)
|
2011-11-30 |
2020-11-04 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
|
JP2015502365A
(ja)
|
2011-12-12 |
2015-01-22 |
オンコイミューニン，インコーポレイティド |
オリゴヌクレオチドのイン−ビボ送達
|
|
CN102675386B
(zh)
|
2011-12-24 |
2014-07-02 |
河南科技大学 |
一种龙胆苦苷分离提纯方法
|
|
WO2013134558A1
(en)
|
2012-03-07 |
2013-09-12 |
The Texas A & M University System |
Cancer treatment targeting non-coding rna overexpression
|
|
AU2013232378B2
(en)
|
2012-03-13 |
2017-09-28 |
Gilead Sciences, Inc. |
2'- substituted carba-nucleoside analogs for antiviral treatment
|
|
KR20130114435A
(ko)
|
2012-04-09 |
2013-10-17 |
삼성전자주식회사 |
다수의 전극을 갖는 생분자 검출 장치
|
|
CA2870697C
(en)
|
2012-04-23 |
2021-11-23 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
|
|
GEP20176800B
(en)
|
2012-05-22 |
2018-01-10 |
Idenix Pharmaceuticals Llk |
D-amino acid compounds for liver disease
|
|
US9284344B2
(en)
|
2012-05-30 |
2016-03-15 |
Hokkaido System Science Co., Ltd. |
Oligonucleotide synthesis method using highly dispersible liquid-phase support
|
|
KR20240148947A
(ko)
|
2012-07-13 |
2024-10-11 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
|
JP2015525797A
(ja)
|
2012-08-06 |
2015-09-07 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
糖質コンジュゲートｒｎａ剤およびその調製方法
|
|
US9403865B2
(en)
|
2012-08-15 |
2016-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified capping protocols
|
|
CA2887884A1
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
US10443052B2
(en)
|
2012-10-15 |
2019-10-15 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating C9ORF72 expression
|
|
ES2762326T5
(es)
|
2012-10-15 |
2023-04-27 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de C9ORF72
|
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
|
RU2015119999A
(ru)
|
2012-10-29 |
2016-12-20 |
Кокристал Фарма, Инк. |
Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака
|
|
EP2725029A1
(en)
|
2012-10-29 |
2014-04-30 |
Laboratoire Biodim |
New antibacterial compounds and biological applications thereof
|
|
EP2915815B1
(en)
|
2012-10-31 |
2018-01-17 |
Takeda Pharmaceutical Company Limited |
New modified nucleic acid
|
|
JP6452614B2
(ja)
|
2012-11-15 |
2019-01-16 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲート
|
|
US9725723B2
(en)
|
2012-11-26 |
2017-08-08 |
Roche Innovation Center Copenhagen A/S |
Compositions and methods for modulation of FGFR3 expression
|
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
DK2951305T3
(en)
|
2013-01-30 |
2018-10-29 |
Hoffmann La Roche |
LNA oligonucleotide KULHYDRATKONJUGATER
|
|
WO2014121287A2
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
EP3366772A1
(en)
|
2013-02-22 |
2018-08-29 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
|
|
US20160050930A1
(en)
|
2013-03-28 |
2016-02-25 |
Syngenta Limited |
Methods of controlling neonicotinoid resistant pests
|
|
WO2014154486A1
(en)
|
2013-03-28 |
2014-10-02 |
Syngenta Participations Ag |
Methods of controlling neonicotinoid resistant pests
|
|
PE20152002A1
(es)
|
2013-05-01 |
2016-01-21 |
Isis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de ttr y vhb
|
|
CN105228999B
(zh)
|
2013-05-24 |
2021-03-02 |
味之素株式会社 |
吗啉代寡核苷酸的制备方法
|
|
CN105247052A
(zh)
|
2013-05-24 |
2016-01-13 |
罗氏创新中心哥本哈根有限公司 |
B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途
|
|
WO2014205451A2
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
SG10201908122XA
(en)
|
2013-06-27 |
2019-10-30 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
|
TWI772856B
(zh)
|
2013-07-19 |
2022-08-01 |
美商百健Ｍａ公司 |
用於調節τ蛋白表現之組合物
|
|
WO2015013673A1
(en)
|
2013-07-25 |
2015-01-29 |
Aurasense Therapeutics, Llc |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
|
EP3027617B1
(en)
|
2013-07-31 |
2026-02-18 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
CN105579442A
(zh)
|
2013-09-06 |
2016-05-11 |
先正达参股股份有限公司 |
杀虫化合物
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
WO2015051366A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
|
MX2016004651A
(es)
|
2013-10-11 |
2016-08-05 |
Ionis Pharmaceuticals Inc |
Composiciones para modular la expresion de c9orf72.
|
|
WO2015057727A1
(en)
|
2013-10-14 |
2015-04-23 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
AU2014337506B2
(en)
|
2013-10-14 |
2020-10-15 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
NZ719477A
(en)
|
2013-11-11 |
2022-05-27 |
Sangamo Therapeutics Inc |
Methods and compositions for treating huntington’s disease
|
|
HK1220724A1
(zh)
|
2013-11-14 |
2017-05-12 |
罗氏创新中心哥本哈根有限公司 |
Apob反义缀合物化合物
|
|
EP3053585A1
(en)
|
2013-12-13 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
EP3095460A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP3647318B1
(en)
|
2014-04-28 |
2021-06-30 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
ES2844593T3
(es)
|
2014-05-01 |
2021-07-22 |
Ionis Pharmaceuticals Inc |
Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
|
|
MX378789B
(es)
|
2014-05-08 |
2025-03-11 |
Sangamo Biosciences Inc |
Métodos y composiciones para tratar la enfermedad de huntington.
|
|
JP6663859B2
(ja)
|
2014-05-20 |
2020-03-13 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
ハンチントン病の治療化合物
|
|
US20160017327A1
(en)
|
2014-07-11 |
2016-01-21 |
The Johns Hopkins University |
Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
EP2982758A1
(en)
|
2014-08-04 |
2016-02-10 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Genome editing for the treatment of huntington's disease
|
|
ES2799409T3
(es)
|
2014-08-07 |
2020-12-17 |
Takeda Pharmaceuticals Co |
Lípido catiónico
|
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
|
WO2016037191A1
(en)
|
2014-09-05 |
2016-03-10 |
Health Research, Inc. |
Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
|
|
JP2017536119A
(ja)
|
2014-11-19 |
2017-12-07 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラルホスホロチオエート連結を含むｌｎａギャップマーオリゴヌクレオチド
|
|
EP3234131B1
(en)
|
2014-12-16 |
2020-04-22 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
SMT201900347T1
(it)
|
2014-12-24 |
2019-07-11 |
Uniqure Ip Bv |
Soppressione del gene huntingtina indotta da rnai
|
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
US11761951B2
(en)
|
2015-02-04 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
|
EP3253871A1
(en)
|
2015-02-04 |
2017-12-13 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
|
SG11201706444TA
(en)
|
2015-02-10 |
2017-09-28 |
Genzyme Corp |
VARIANT RNAi
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
|
|
US10370659B2
(en)
|
2015-02-23 |
2019-08-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing antisense activity
|
|
US20180036335A1
(en)
|
2015-03-03 |
2018-02-08 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
|
WO2016145142A1
(en)
|
2015-03-10 |
2016-09-15 |
Emory University |
Nucleotide and nucleoside therapeutics compositions and uses related thereto
|
|
WO2016154096A1
(en)
|
2015-03-20 |
2016-09-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of smggds expression
|
|
CN107980062B
(zh)
|
2015-04-03 |
2022-11-25 |
马萨诸塞大学 |
用于靶向亨廷汀mRNA的寡核苷酸化合物
|
|
WO2016164896A2
(en)
|
2015-04-10 |
2016-10-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of smn expression
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
EP3722424A1
(en)
|
2015-04-16 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
US11414657B2
(en)
|
2015-06-29 |
2022-08-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
|
MY192997A
(en)
|
2015-07-10 |
2022-09-20 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
US11053495B2
(en)
|
2015-07-17 |
2021-07-06 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
|
CN108025089A
(zh)
|
2015-07-22 |
2018-05-11 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
US20180216114A1
(en)
|
2015-07-27 |
2018-08-02 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
|
PL3329002T3
(pl)
|
2015-07-31 |
2021-04-19 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
|
|
DK3341479T3
(da)
|
2015-08-24 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
LNA-G-Proces
|
|
IL293355B2
(en)
|
2015-08-25 |
2024-07-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
|
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20180273573A1
(en)
|
2015-10-01 |
2018-09-27 |
Memorial Sloan-Kettering Cancer Center |
Inhibitors of menaquinone biosynthesis
|
|
WO2017059446A1
(en)
|
2015-10-01 |
2017-04-06 |
Memorial Sloan-Kettering Cancer Center |
Anthranilyl-adenosinemonosulfamate analogs and uses thereof
|
|
EP3355932B1
(en)
|
2015-10-02 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
SG10201912902TA
(en)
|
2015-10-09 |
2020-02-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
WO2017067970A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
|
WO2017079291A1
(en)
|
2015-11-02 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating c90rf72
|
|
IL281211B2
(en)
|
2015-11-12 |
2024-01-01 |
Hoffmann La Roche |
Oligonucleotides for inducing paternal ube3a expression
|
|
AU2017234150B2
(en)
|
2016-03-13 |
2021-09-16 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
TWI840950B
(zh)
|
2016-03-14 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
用於降低pd-l1表現之寡核苷酸
|
|
US11267843B2
(en)
|
2016-03-18 |
2022-03-08 |
Roche Innovation Center Copenhagen A/S |
Stereodefining L-monomers
|
|
WO2017165489A1
(en)
|
2016-03-23 |
2017-09-28 |
Emory University |
Antiviral agents for treating zika and dengue virus infections
|
|
US20190142856A1
(en)
|
2016-04-13 |
2019-05-16 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
|
CN109153697A
(zh)
|
2016-04-14 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
三苯甲基-单-GalNAc化合物及其用途
|
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
|
CN109477108A
(zh)
|
2016-05-04 |
2019-03-15 |
波涛生命科学有限公司 |
寡核苷酸组合物和其方法
|
|
CN109311925B
(zh)
|
2016-05-12 |
2022-06-03 |
罗氏创新中心哥本哈根有限公司 |
立体限定的氧杂氮杂磷杂环戊烷亚磷酰胺单体与核苷或寡核苷酸的增强的偶联
|
|
CA3023621C
(en)
|
2016-05-13 |
2021-07-27 |
F. Hoffmann-La Roche Ag |
Protein-based sample collection matrices and devices
|
|
EP3458464A1
(en)
|
2016-05-18 |
2019-03-27 |
ETH Zurich |
Stereoselective synthesis of phosphorothioate oligoribonucleotides
|
|
WO2017210647A1
(en)
|
2016-06-03 |
2017-12-07 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
WO2017221883A1
(ja)
|
2016-06-20 |
2017-12-28 |
武田薬品工業株式会社 |
抗体－薬物コンジュゲート
|
|
US20190264267A1
(en)
|
2016-07-25 |
2019-08-29 |
Wave Life Sciences Ltd. |
Phasing
|
|
JP7296882B2
(ja)
|
2016-11-23 |
2023-06-23 |
ウェイブ ライフ サイエンシズ リミテッド |
ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
|
|
WO2018223056A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CN120330183A
(zh)
|
2017-06-02 |
2025-07-18 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
US11597927B2
(en)
|
2017-06-02 |
2023-03-07 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2018237194A1
(en)
|
2017-06-21 |
2018-12-27 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
CA3072076A1
(en)
|
2017-08-08 |
2019-02-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
SG11202000276YA
(en)
|
2017-09-18 |
2020-04-29 |
Wave Life Sciences Ltd |
Technologies for oligonucleotide preparation
|
|
WO2019075357A1
(en)
|
2017-10-12 |
2019-04-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
BR112020020670A2
(pt)
|
2018-04-12 |
2021-03-02 |
Wave Life Sciences Ltd. |
composição de oligonucleotídeo, composição farmacêutica, método para alterar o splicing de uma transcrição alvo, método para tratar distrofia muscular, método para preparar um oligonucleotídeo ou uma composição de oligonucleotídeo do mesmo e oligonucleotídeo
|
|
TWI844541B
(zh)
|
2018-05-11 |
2024-06-11 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組成物及其使用方法
|
|
AU2019392928A1
(en)
|
2018-12-06 |
2021-06-17 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
SG11202107318YA
(en)
|
2019-02-01 |
2021-08-30 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
JP2022525541A
(ja)
|
2019-03-20 |
2022-05-17 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド調製に有用な技術
|
|
JPWO2020196662A1
(es)
|
2019-03-25 |
2020-10-01 |
|
|
|
BR112021021203A2
(pt)
|
2019-04-25 |
2022-01-04 |
Wave Life Sciences Ltd |
Oligonucleotídeo; composição de oligonucleotídeo quiralmente controlada; composição farmacêutica; método para prevenir, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a e/ou prevenir, atrasar o início, desenvolvimento e/ou progresso, e/ou tratar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para aumentar o nível de salto de um éxon prejudicial em uma transcrição de gene ush2a ou seu produto de gene em uma célula; método para prevenir, atrasar o início ou progressão de, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para saltar um éxon prejudicial 13 em um alelo de ush2a em um indivíduo; método para produzir ou aumentar o nível de um éxon de proteína ush2a com salto 13 em um sistema; e composto, oligonucleotídeo, composição ou método
|
|
US20230145795A1
(en)
|
2019-04-25 |
2023-05-11 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CN114502177A
(zh)
|
2019-05-09 |
2022-05-13 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
CA3156176A1
(en)
|
2019-10-06 |
2021-04-15 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
BR112022006205A2
(pt)
|
2019-10-06 |
2022-07-19 |
Wave Life Sciences Ltd |
Oligonucleotídeo; composição farmacêutica; composição de oligonucleotídeo; fosforamidita; método de preparação de um oligonucleotídeo ou composição; método para caracterizar um oligonucleotídeo ou uma composição; método para modificar uma adenosina alvo em um ácido nucleico alvo; método para desaminar uma adenosina alvo em um ácido nucleico alvo; método para prevenção ou tratamento de uma afecção, distúrbio ou doença passível de uma mutação de g para a; e composto, oligonucleotídeo, composição ou método
|
|
WO2021178237A2
(en)
|
2020-03-01 |
2021-09-10 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
IL298406A
(en)
|
2020-05-22 |
2023-01-01 |
Wave Life Sciences Ltd |
Double stranded oligonucleotide compositions and methods relating thereto
|
|
AU2021277407A1
(en)
|
2020-05-22 |
2022-11-17 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2022046667A1
(en)
|
2020-08-24 |
2022-03-03 |
Wave Life Sciences Ltd. |
Cells and non-human animals engineered to express adar1 and uses thereof
|
|
EP4200616A1
(en)
|
2020-08-24 |
2023-06-28 |
Wave Life Sciences Ltd. |
Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays
|
|
WO2022067023A1
(en)
|
2020-09-24 |
2022-03-31 |
Mayo Foundation For Medical Education And Research |
Screening platforms
|
|
CA3197311A1
(en)
|
2020-11-08 |
2022-05-12 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
CN116507724A
(zh)
|
2020-11-08 |
2023-07-28 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
WO2023049477A2
(en)
|
2021-09-26 |
2023-03-30 |
Wave Life Sciences Ltd. |
Compositions for editing mecp2 transcripts and methods thereof
|
|
KR20240063964A
(ko)
|
2021-09-26 |
2024-05-10 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 방법
|
|
WO2023075766A1
(en)
|
2021-10-27 |
2023-05-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2023076352A2
(en)
|
2021-10-27 |
2023-05-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2023154528A1
(en)
|
2022-02-11 |
2023-08-17 |
Wave Life Sciences Ltd. |
Stereoselective technologies for chiral compounds
|
|
AU2023227808A1
(en)
|
2022-03-02 |
2024-09-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof for exon skipping
|
|
EP4507700A2
(en)
|
2022-04-15 |
2025-02-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods relating thereto
|
|
WO2023220440A1
(en)
|
2022-05-12 |
2023-11-16 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
CN120476205A
(zh)
|
2022-08-11 |
2025-08-12 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|